Literature DB >> 17219961

Anticancer activities of trichostatin A on maligant lymphoid cells.

Chunyan Sun1, Xinyue Liu, Yan Chen, Fang Liu.   

Abstract

The anticancer activity of trichostain A (TSA) on human B cell non-Hodgkin's lymphoma and its mechanism were explored. The effect of TSA on the growth of Raji cells and normal peripheral blood mononuclear cells (NPBMNC) was studied by MTT assay. The effect of TSA on the apoptosis of Raji cells and NPBMNC was studied by flow cytometry and TDT-mediated dUTP nick end labeling (TUNEL). The effect of TSA on the cell cycle of Raji cells was studied by propidium iodide method. The results showed that TSA potently inhibited proliferation of Raji cells at microgram concentrations and induced apoptosis of Raji cells in a time- and concentration-dependent manner. Treatment with TSA induced accumulation of cells in G0/G1 or G2/M and a concomitant decrease of cell population in S phase. However, NPBMNC was less sensitive to the cytotoxic effect of TSA than Raji cells. It was concluded that TSA may inhibit the proliferation of Raji cells by regulating the cell cycle and inducing the cell apoptosis. Moreover, TSA demonstrates low toxicity in NPBMNC but selectively induces apoptosis of Raji cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17219961     DOI: 10.1007/s11596-006-0513-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  14 in total

Review 1.  Histone deacetylases, transcriptional control, and cancer.

Authors:  W D Cress; E Seto
Journal:  J Cell Physiol       Date:  2000-07       Impact factor: 6.384

2.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.

Authors:  D M Vigushin; S Ali; P E Pace; N Mirsaidi; K Ito; I Adcock; R C Coombes
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.

Authors:  M S Finnin; J R Donigian; A Cohen; V M Richon; R A Rifkind; P A Marks; R Breslow; N P Pavletich
Journal:  Nature       Date:  1999-09-09       Impact factor: 49.962

5.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

Authors:  P N Munster; T Troso-Sandoval; N Rosen; R Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

Review 6.  Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.

Authors:  T Owa; H Yoshino; K Yoshimatsu; T Nagasu
Journal:  Curr Med Chem       Date:  2001-10       Impact factor: 4.530

Review 7.  Butyrate as a model for "gene-regulating chemoprevention and chemotherapy.".

Authors:  Y Sowa; T Sakai
Journal:  Biofactors       Date:  2000       Impact factor: 6.113

8.  Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.

Authors:  L Huang; A B Pardee
Journal:  Mol Med       Date:  2000-10       Impact factor: 6.354

9.  The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells.

Authors:  Christoph Herold; Marion Ganslmayer; Matthias Ocker; Martin Hermann; Albert Geerts; Eckhart G Hahn; Detlef Schuppan
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

10.  Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells.

Authors:  M Murata; M Towatari; H Kosugi; M Tanimoto; R Ueda; H Saito; T Naoe
Journal:  Jpn J Cancer Res       Date:  2000-11
View more
  2 in total

Review 1.  Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy.

Authors:  Leila Haery; Ryan C Thompson; Thomas D Gilmore
Journal:  Genes Cancer       Date:  2015-05

2.  Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines.

Authors:  Alexandra Y Tsidulko; Liudmila Matskova; Lidiia A Astakhova; Ingemar Ernberg; Elvira V Grigorieva
Journal:  Oncotarget       Date:  2015-12-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.